Moderna prevails in COVID-19 vaccine row at EPO

Despite attempts by Pfizer and BioNTech to invalidate the patent, the ruling strengthens Moderna’s position in ongoing global litigation | Pfizer is considering an appeal, while BioNTech remains steadfast in defending its innovations.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

Moderna’s COVID-19 pledge dilemma

16 May 2024 As the company challenges Pfizer and BioNTech over COVID-19 vaccine patents, issues over the enforceability of pledges made during the pandemic may make pharma think twice in future, finds Marisa Woutersen.

Big Pharma

Pfizer must hand over COVID-19 vaccine knowledge

19 September 2023 Moderna alleges that rivals’ vaccine infringes patents filed covering a foundational mRNA technology | Big pharma firm must “specifically describe” awareness of Moderna's work in the mRNA vaccine sphere before the end of the month.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Moderna prevails in COVID-19 vaccine row at EPO

More on this story

Editor's picks

Editor's picks

More features